Minutes of PPAR-γ agonism and neuroprotection

Peroxisome proliferator-activated receptor gamma (PPAR-γ) is one of the ligand-activated transcription factors which regulates a number of central events and considered as a promising target for various neurodegenerative disease conditions. Numerous reports implicate that PPAR-γ agonists have shown neuroprotective effects by regulating genes transcription associated with the pathogenesis of neurodegeneration. In regards, this review critically appraises the recent knowledge of PPAR-γ receptors in neuroprotection in order to hypothesize potential neuroprotective mechanism of PPAR-γ agonism in chronic neurological conditions. Of note, the PPAR-γ′s interaction dynamics with PPAR-γ coactivator-1α (PGC-1α) has gained significant attention for neuroprotection. Likewise, a plethora of studies suggest that the PPAR-γ pathway can be actuated by the endogenous ligands present in the CNS and thus identification and development of novel agonist for the PPAR-γ receptor holds a vow to prevent neurodegeneration. Together, the critical insights of this review enlighten the translational possibilities of developing novel neuroprotective therapeutics targeting PPAR-γ for various neurodegenerative disease conditions. •PPAR-γ dependent PGC-1α signalling activation could regulate multiple gene transcriptions involved in neurodegeneration.•PGC1-α signalling will regulate microglial activation, inflammatory cascades, oxidative stress and mitochondrial biogenesis.•Finest target for various neurodegenerative disorders (NDDs).•PPAR-ϒ agonism along with other pharmacological agents targeting different pathways could be an effective strategy for NDDs.